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Current inactivated influenza vaccines provide protec-
tion when vaccine antigens and circulating viruses share a
high degree of similarity in hemagglutinin protein. Five anti-
genic sites in the hemagglutinin protein have been pro-
posed, and 131 amino acid positions have been identified
in the five antigenic sites. In addition, 20, 18, and 32 amino
acid positions in the hemagglutinin protein have been iden-
tified as mouse monoclonal antibody–binding sites, posi-
tively selected codons, and substantially diverse codons,
respectively. We investigated these amino acid positions
for predicting antigenic variants of influenza A/H3N2 virus-
es in ferrets. Results indicate that the model based on the
number of amino acid changes in the five antigenic sites is
best for predicting antigenic variants (agreement = 83%).
The methods described in this study could be applied to
predict vaccine-induced cross-reactive antibody responses
in humans, which may further improve the selection of vac-
cine strains.
I
nfluenza viruses cause substantial medical and social
problems throughout the world, and vaccination is the
primary method for preventing influenza and its complica-
tions. Of the three types of influenza viruses (A, B, and C),
only influenza Aand B viruses cause epidemic human dis-
ease. Hemagglutinin (HA) and neuraminidase proteins are
the two surface antigens that induce protective antibody
responses and are the basis for subtyping influenza A
viruses. Influenza B viruses are not categorized into sub-
types (1). Since 1977, influenza A/H1N1, A/H3N2, and B
viruses have been in global circulation, and these three
viruses are currently included as vaccine components.
Current inactivated vaccines provide essential protection
when the vaccine antigens and the circulating viruses share
high degree of similarity in the HA protein. Since new
influenza virus antigenic variants emerge frequently from
accumulation of point mutations in the HA protein (i.e.,
antigenic drift), influenza vaccine antigens need to be
updated frequently, based on the results of global influen-
za surveillance (1), which includes clinical, virologic, and
immunologic surveillance. In virologic surveillance,
influenza viruses are characterized antigenically on the
basis of ferret serum antibody cross-reactivity. Antigenic
variants selected serologically are then tested for antibody
cross-reactivity in human sera to evaluate the potential
cross-protection against the antigenic variants provided by
the current vaccines and to select vaccine strains for the
next season (2,3). 
The HA protein of influenza viruses is synthesized as a
single polypeptide (HA0) that is subsequently cleaved into
two polypeptides (HA1 and HA2) and forms into
homotrimers. The HA1 polypeptide mutates more fre-
quently than the HA2 polypeptide and plays a major role in
natural selection (4,5). Three-dimensional (3-D) structure
of the HA protein of A/Aichi/2/68 (H3N2) has been deter-
mined, and five antigenic sites on the HA1 polypeptide
have been proposed conceptually (4–6). Of the 329 amino
acid positions on HA1, 131 lie on or near the five antigenic
sites (7,8). Twenty amino acid positions on HA1 have been
mapped, based on laboratory variants selected in the pres-
ence of mouse monoclonal antibodies (9,10). In addition,
18 amino acid positions have been identified as being
under positive selection by comparing 357 viruses isolated
from 1984 to 1996 (7). In a recent study, 32 amino acid
positions have been identified as diverse codons by com-
paring 525 viruses isolated from 1968 to 2000 (11).
However, the importance of these amino acid positions in
terms of predicting antibody cross-reactivity is unclear.
Therefore, we conducted this study to explore the useful-
ness of these amino acid positions for predicting antigenic
variants of influenza A/H3N2 viruses. The methods
described in this study could be used to predict vaccine-
induced cross-reactive antibody responses in humans,
which may further improve the selection of vaccine strains.
Methods
Cross-Reactive Antibody Data
In the current global influenza surveillance system,
influenza viruses are characterized antigenically based on
ferret serum hemagglutinin-inhibition (HAI) antibody
cross-reactivity. We first screened publications for
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we searched the H3N2 viruses with cross-reactive anti-
body data for their amino acid sequences of the HA1
polypeptide (www.flu.lanl.gov) (8). Table 1 shows the full
name, abbreviation, identification (ID) by type, and acces-
sion code of the H3N2 viruses (12–16). Six sets of ferret
serum HAI cross-reactivity data were available for analy-
sis. The first set included 11 viruses (55 pairwise compar-
isons, virus ID: A to K) isolated from 1971 to 1979 (12).
The second set included 8 viruses (28 pairwise compar-
isons, virus ID: J, L to R) isolated from 1979 to 1987 (17).
The third set included 10 viruses (45 pairwise compar-
isons, virus ID: S to AB) isolated from 1989 to 1994 (13).
The fourth set included 8 viruses (28 pairwise compar-
isons, virus ID: AC to AJ) isolated from 1994 to 1996 (18).
The fifth set included 5 viruses (10 pairwise comparisons,
virus ID: AE, AK to AN) isolated from 1995 to 1999 (15).
The sixth set included 6 viruses (15 pairwise comparisons,
virus ID: AN to AT) isolated from 1999 to 2002 (16). A
mathematical method had been proposed to calculate
“antigenic relatedness” between two viruses (presented as
a percentage) as a geometric mean of two ratios between
the heterologous and homologous antibody titers (19,20). 
Since our study investigates the relationship between
antigenic difference and amino acid changes in the HA1
polypeptide, the mathematical method was modified to cal-
culate “antigenic distance” (i.e., reciprocal of antigenic
relatedness). For example, if homologous titers of two
viruses are 640 and 640 and two heterologous titers against
each other are 320 and 320, the antigenic relatedness
between these two viruses is ([320 x 320]/[640 x 640])½  =
50%, and the antigenic distance between these two viruses
is ([640 x 640]/[320 x 320])½  = 2. Table 2 shows the anti-
genic distances of the 55 pairwise comparisons among the
11 viruses in the first set. In total, 181 pairwise comparisons
among 45 viruses were available for analysis. Among the
181 pairwise comparisons, 56 (31%) have an antigenic dis-
tance <4 (i.e., similar antigenicity), and 125 (69%) have an
antigenic distance >4 (i.e., antigenic variant) (21).
Sequence Alignment
Amino acid sequences of the HA1 polypeptide were
downloaded from the Los Alamos Influenza Sequence
Database (8) or entered from the original publications if
they were not available from the Los Alamos Influenza
Sequence Database. Amino acid sequences of the 45 virus-
es were harmonized to same length (329 residues) and
were numbered according to A/Aichi/2/68 HA1 sequence
because the 3-D structure of the A/Aichi/2/68 hemagglu-
tinin protein has been determined (4–6). Pairwise align-
ments among the 45 sequences were conducted by using
S-Plus 2000 (Insightful Corporation, Seattle, WA).
Pairwise-aligned amino acid sequence data were trans-
formed into 0 (without change) and 1 (with change) and
were further linked with the pairwise antigenic distance
data for predicting analyses. 
Predicting Antigenic Variants
The first model was based on amino acid differences in
the whole HA1 polypeptide (329 residues). The second
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Table 1. Full name, identification (ID), abbreviation, and 
accession code of influenza H3N2 viruses  
Full name  ID  Abbreviation  Accession no. 
A/Hong Kong/107/71   A  HK71  ISDNHK71 
A/England/42/72   B  ENG72  ISDNENG72 
A/Port Chalmers/1/73   C  PC73  ISDNPC73 
A/Mayo Clinic/1/75   D  MC75  ISDNMC75 
A/Victoria/3/75   E  VIC75  ISDNVIC75 
A/Tokyo/1/75  F  TOK75  ISDNTOK75 
A/England/864/75   G  ENG75  ISDNENG75 
A/Allegheny County 
/29/76 
H  AC76  Direct entry (12) 
A/Victoria/112/76   I  VIC76  Direct entry (12) 
A/Bangkok/1/79  J  BAN179  ISDNBK179 
A/Bangkok/2/79  K  BAN279  ISDNBK279 
A/Philippines/2/ 82  L  PHI82  ISDNPH282 
A/Mississippi/1/85   M  MIS85  AF008893 
A/Leningrad/360/86   N  LEN86  AF008903 
A/Shanghai/11/87   O  SHA87  AF008886 
A/Sichuan/2/87  P  SIC87  AF008884 
A/Sydney/1/87  Q  SYD87  AF008882 
A/Victoria/7/87   R  VIC87  AF008888 
A/Beijing/353/89   S  BEI89  Z46391 
A/Hong Kong/34/90   T  HK90  Z46409 
A/Beijing/32/92   U  BEI92  Direct entry (13)  
A/Hong Kong/23/92   V  HK92  Direct entry (13)  
A/Guangdong/25/93   W  GUA93  Z46406 
A/Madrid/252/93   X  MAD93  Z46411 
A/Scotland/142/93   Y  SCO142  Z46413 
A/Scotland/160/93   Z  SCO160  Z46414 
A/Shangdong/9/93   AA  SHA93  Z46417 
A/Hong Kong/1/94   AB  HK94  Z46407 
A/Johannesburg/33/94   AC  JOH94  AF008774 
A/Alaska/10/95  AD  ALA95  AF008748 
A/Nanchang/933/95   AE  NCH95  AF008725 
A/Wuhan/359/95  AF  WHN95  AF008722 
A/Auckland/5/96   AG  AUC96  AF008714 
A/Fujian/47/96  AH  FUJ96  AF008726 
A/New York/37/96   AI  NY96  AF180650 
A/South 
Africa/1147/96 
AJ  SA96  Direct entry (14) 
A/Sydney/5/97  AK  SYD97  ISDNASYD97 
A/Ireland/10586/99   AL  IRE99  Direct entry (15) 
A/Moscow/10/99  AM  MOS99  ISDN13277 
A/Panama/2007/99   AN  PAN99  ISDNCDA001 
A/Fujian/140/2000   AO  FUJ00  Direct entry (16)  
A/Chile/6416/2001   AP  CHI01  Direct entry (16)  
A/New York/55/2001   AQ  NY01  Direct entry (16)  
A/Fujian/411/2002   AR  FUJ02  ISDN38157 
A/Hong Kong/ 
1550/2002 
AT  HK02  Direct entry (16)  model was based on amino acid differences in the five
antigenic sites (131 residues) (online Appendix available
at www.cdc.gov/ncidod/eid/vol10no8/04-0107.htm#app)
(7,8). The third model was based on the 20 positions relat-
ed to mouse monoclonal antibody binding (online
Appendix) (9,10). The fourth model was based on the 18
positions under positive selection (online Appendix) (7).
The fifth model was based on the 32 codons of substantial
diversity (online Appendix) (11). For evaluating the quali-
tative performance of the five prediction models, an anti-
genic variant was defined as antigenic distance >4 (21).
Positive predictive value (PPV), negative predictive value
(NPV), and agreement of the five prediction models were
calculated, and different cutoff levels of amino acid differ-
ences were compared by using the receiver-operating char-
acteristic analysis (22). 
Results
Model One
Figure A shows the scatterplot between antigenic dis-
tance and number of amino acid changes in the HA1 pep-
tide (328 residues). Among the 181 pairwise comparisons,
the antigenic distance ranged from 1 to 181, and the num-
ber of amino acid changes in the HA1 peptide ranged from
1 to 36. Overall, the antigenic distance correlated to the
number of amino acid changes in the HA1 polypeptide (R
= 0.74, p < 0.001). Different cutoffs of amino acid changes
in the HA1 polypeptide were evaluated for predicting anti-
genic variants. The highest agreement was found with a
cutoff of >7 amino acid changes, which shows that the
NPV, PPV, and agreement were 66% (31/47), 81%
(109/134), and 77% (140/181), respectively (Figure A). 
Table 3 shows some unique pairwise comparisons with
unusual patterns between antigenic distances and amino
acid changes. A/Shanghai/11/87 and A/Victoria/7/87 were
antigenically different (antigenic distance = 5.7), but they
had only one amino acid difference (R247S). The position
247 is located at the antigenic site D. In addition to the
amino acid change at position 247, A/Shanghai/11/87 had
two more amino acid differences from A/Sichuan/2/87
(E156K, S186V) and A/Sydney/1/87 (A138S, N193K), but
these three viruses were antigenically similar (antigenic
distance <4). A/Victoria/7/87 had only two amino acid dif-
ferences from A/Sichuan/2/87 (K156E, V186S) and
A/Sydney/1/87 (S138A, K193N), but A/Victoria/7/87 was
antigenically different from these two viruses (Table 3).
The positions 156, 186, and 193 are located at the anti-
genic site B and the position 138 is located at the antigenic
site A. Moreover, the positions 156 and 193 are also locat-
ed at the mouse monoclonal antibody-binding sites (online
Appendix).
The unusual patterns between antigenic distances and
amino acid differences may be due to interaction between
amino acid changes in the hemagglutinin or laboratory
variability, which needs further experiments to clarify. In
addition, A/Victoria/3/75 and A/Victoria/112/76 had only
two amino acid differences (L3F, R229G), but they were
antigenically different (antigenic distance = 5.7) (Table 3),
which also requires further experiments to clarify. The
position 3 is not located at any antigenic site, and the posi-
tion 229 is located at the antigenic site D. We found that 3
of 80 pairwise comparisons with >12 amino acid changes
had antigenic distance <4 (Figure A).
A/Sydney/5/97 and A/Panama/2007/99 had 12 amino
acid differences, but these two viruses were antigenically
similar (antigenic distance = 1.4) based on ferret serum
HAI titers (Table 3). However, inactivated vaccines con-
taining A/Sydney/5/97 induced low serum antibody titers
against A/Panama/2007/99 in humans; therefore,
A/Sydney/5/97 was replaced by A/Panama/2007/99 as the
vaccine strain for the 2000–01 season (3).
A/HK/1550/2002 had 12 amino acid differences from
A/Chile/6416/01 and 14 amino acid differences from
A/Fujian/140/2000, but A/HK/1550/2002 was antigenical-
ly similar to these two viruses (Table 3). These three com-
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Table 2. Antigenic distance (upper right) and number of amino acid changes in the HA1 (lower left) in 55 pairwise comparisons among 
11 influenza H3N2 viruses  
H3N2 virus 
Virus ID
a  A  B  C  D  E  F  G  H  I  J  K 
A. HK/71    27.7  19.6  39.2  55.4  39.2  48.0  39.2  110.9  67.9  110.9 
B. ENG/72  15    4.0  26.1  16.0  64.0  156.8  4.0  64.0  78.4  181.0 
C. PC/73  16  7    8.0  16.0  32.0  27.7  22.6  37.0  55.4  90.5 
D. MC/75  21  12  12    9.2  32.0  45.3  32.0  90.5  55.4  90.5 
E. VIC/75  30  19  19  15    11.3  27.7  1.9  5.7  78.4  128.0 
F. TOK/75  20  17  18  16  20    78.4  45.3  26.1  39.2  90.5 
G. ENG/75  27  18  17  8  17  22    32.0  4.6  6.9  19.6 
H. AC/76  31  20  18  16  6  21  19    9.2  78.4  73.9 
I. VIC/76  32  21  19  17  2  22  19  4    27.7  32.0 
J. BAN/1/79  36  25  23  21  24  33  17  26  26    9.2 
K. BAN/2/79  36  24  24  22  26  33  20  28  28  3   
aID, identification.  
 parisons may indicate that interaction of multiple amino
acid changes could potentially preserve the 3-D structure
of HA1. Alternatively, the ferret serum HAI assay system
is not sensitive enough to detect the antigenic difference. 
Model Two
Figure B shows the scatterplot between antigenic dis-
tance and number of amino acid changes in the five anti-
genic sites (131 amino acid positions). Among the 181
pairwise comparisons, amino acid changes in the five anti-
genic sites ranged from 1 to 32. Overall, the antigenic dis-
tance correlated to number of amino acid changes in the
five antigenic sites (R = 0.77, p < 0.001). Different cutoffs
of amino acid changes in the five antigenic sites were eval-
uated for predicting antigenic variants. The highest agree-
ment was found by using a cutoff of >7 amino acid
changes, which shows that the NPV was 71% (42/59),
PPV was 89% (108/122), and agreement was 83%
(150/181) (Figure B). 
Model Three
Figure C shows the scatter plot between antigenic dis-
tance and number of amino acid changes in the 20 amino
acid positions related to mouse monoclonal antibody bind-
ing. Overall, the antigenic distance correlated to number of
amino acid changes in the 20 amino acid positions (R =
0.74, p < 0.001). Different cutoffs of amino acid changes
in the previously defined 20 amino acid positions were
evaluated for predicting antigenic variants. The highest
agreement was found by using a cutoff of >2 amino acid
changes, which shows that the NPV was 64% (32/50),
PPV was 82% (107/131), and agreement was 77%
(139/181) (Figure C). 
Model Four
Figure D shows the scatterplot between antigenic dis-
tance and number of amino acid changes in the 18 amino
acid positions under positive selection. Overall, the anti-
genic distance correlated moderately to number of amino
acid changes in the 18 amino acid positions (R = 0.43, p <
0.001). Different cutoffs of amino acid changes in the 18
amino acid positions were evaluated for predicting anti-
genic variants. The highest agreement was found by using
a cutoff of >1 amino acid changes, which shows that the
NPV was 55% (6/11), PPV was 71% (120/170), and agree-
ment was 70% (126/181) (Figure D). 
Model Five
Figure E shows the scatter plot between antigenic dis-
tance and number of amino acid changes in the 32 codons
with substantial diversity. Overall, the antigenic distance
correlated moderately to number of amino acid changes in
the 32 codons (R = 0.68, p < 0.001). Different cutoffs of
amino acid changes in the 32 codons were evaluated for
predicting antigenic variants. The highest agreement was
found by using a cutoff of >2 amino acid changes, which
shows that the NPV was 72% (13/18), PPV was 74%
(120/163), and agreement was 74% (133/181) (Figure E).
Overall, the model based on the number of amino acid
changes in the five antigenic sites has the highest correlation
to the antigenic distance (R = 0.77) and the best perform-
ance for predicting antigenic variants (agreement = 83%).
Discussion
Wilson and Cox proposed that a drift variant of epi-
demiologic importance usually contains >4 amino acid
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Figure. Performance of the five prediction models. Solid line at
each plot, regression; horizontal dashed line, cutoff of antigenic
distance >4; vertical dashed line, cutoff of number of amino acid
changes. Numbers at the four corners indicate true negative
(lower left), false negative (upper left), true positive (upper right),
false positive (lower right) in each prediction model. A) The first
model was based on amino acid differences in the whole HA1
polypeptide (329 residues). B) The second model was based on
amino acid differences in the five antigenic sites (131 residues). C)
The third model was based on the 20 positions related to mouse
monoclonal antibody binding. D) The fourth model was based on
the 18 positions under positive selection. E) The fifth model was
based on the 32 codons with substantial diversity.changes located on >2 of the five antigenic sites, but they
did not specify the amino acid positions in the five anti-
genic sites (5). Our study further showed that the model
based on the number of amino acid changes in the 131
amino acid positions in the five antigenic sites had the
highest correlation to the antigenic distance and the best
performance for predicting antigenic variants.
Theoretically, not all 131 amino acid positions in the five
antigenic sites play a critical role in determining antigenic-
ity, and some immunodominant positions (i.e., major anti-
body-binding sites) could be identified by using
bioinformatics models and reverse genetic techniques
(23–25). Amodel based on the immunodominant positions
can potentially have a better performance than the model
based on the five antigenic sites.
The model based on the 20 amino acid positions relat-
ed to mouse monoclonal antibody binding only have mod-
erate performance for predicting antigenic variants (R =
0.74, agreement = 77%), which indicates that mouse and
ferret antibodies may recognize different B-cell epitopes.
In addition, that models four and five have a low perform-
ance for predicting antigenic variants is not surprising,
since these two models identified the amino acid positions
only on the basis of virus sequence data without incorpo-
rating antigenic properties. 
Antigenic variants of influenza viruses are currently
determined with the ferret serum HAI assay. The ferret
serum HAI assay works well to distinguish major drift
variants, but moderate differences are difficult to define
reliably (26). As shown in Table 3, some unusual patterns
between antigenic distance and amino acid changes in the
HA1 may be caused by laboratory variability of the ferret
serum HAI assay. The prediction models proposed in the
present study may perform better if a more reliable assay
system is used. Several studies have shown that neutraliza-
tion assays are more sensitive for detecting influenza virus
antibody responses than HAI assays (27,28). However, tra-
ditional neutralization assays based on cytopathic effect
are labor-intensive and not suitable for a large-scale sur-
veillance system. A simplified EIA-based neutralization
assay may be the potential solution (29).
Several studies have documented that one to three
amino acid changes in the HA1 of influenza H1N1 and
H3N2 viruses could possibly reduce the antigenicity and
efficacy of inactivated vaccines in animal models (30–33),
which are consistent with our results (Table 3). In animal
studies, single mutation at amino acid position 156 of the
HA1 of two H3N2 viruses was linked to the reduced anti-
genicity (32,33). The position 156 is located at the anti-
genic site B and the mouse monoclonal antibody-binding
site (see online Appendix). Overall, this evidence may
indicate the existence of immunodominant positions in the
HA1 and emphasize the importance of identifying the
immunodominant positions to monitor the selection of
vaccine strains and the process of vaccine manufacturing.
The current global surveillance system largely relies on
ferret serum HAI data for selection of influenza vaccine
strains (2,3). In some cases, human and ferret cross-reac-
tive antibody data were not consistent (34,35). The meth-
ods described in this study could be applied to predict
vaccine-induced cross-reactive antibody responses in
humans, which may further improve the selection of vac-
cine strains (35). 
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Table 3. Some unique pairwise comparisons showing antigenic distance and amino acid changes  
Viruses compared   Antigenic distance  (ferret HAI titers)
a  Amino acid changes (antigenic sites)  
A/Shanghai/11/87 vs. A/Victoria/7/87   5.7 ([320 x 320]/[40 x 80]) ½  R247S(D) 
A/Shanghai/11/87 vs. A/Sichuan/2/87   2.8 ([320 x 640]/[160 x 160])  ½  E156K(B), S186V(B), R247S(D)  
A/Shanghai/11/87 vs. A/Sydney/1/87   2.0 ([320 x 320]/[160x 160])  ½  A138S(A), N193K(B), R247S(D)  
A/Sichuan/2/87 vs. A/Victoria/7/87   5.7 ([320 x 640]/[4 0 x 160]) ½  K156E(B),V186S(B)  
A/Sydney/1/87 vs. A/Victoria/7/87   4.0 ([320 x 320]/[80 x 80])  ½  S138A(A), K193N(B)  
A/Victoria/3/75 vs. A/Victoria/112/76   5.7 ([640 x 2,560]/[640 x 80])  ½  L3F, R229G(D) 
A/Sydney/5/97 vs. A/Panama/2007/99   1.4 ([5,120x 2,560]/ [2,560 x 2,560]  ½  I3L, P21S, R57Q(E), Y137S(A), S142R(A), 
I144N(A), D172E(D), H183L, T192I(B), I194L(B), 
I226V(D), H233Y  
A/Fujian/140/2000 vs. A/HK/1550/2002   2.0 ([640 x 640]/[320 x 320])  ½  G14C, A43V, R50G(C), E83K(E), N96S(D), 
S186V(B), V194I(B), P199S,  V202I, W222R, 
G225D, I226V(D), C247S(D), S273P(C)  
A/Chile/6416/01 vs. A/HK/1550/02   2.0 ([320 x 640]/[80 x 640])  ½  R50G(C), E83K(E), N96S(D), V106A, D144N(A), 
G186V(B), L194I(B), V202I, H221P, W222R, 
G225D, K246N(D)  
aHemagglutinin -inhibition (HAI) titers  were shown as two homologous titers divided by two heterologous titers.  References
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